Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

A bioengineered, naturally-derived, sustainable biocide for breaking down organic biofilms formed by drug-resistant bacteria.

Objective

Aequor's ABD (Aequor Biofilm Dispersant) represents a significant leap forward in the arms race between modern medicine and drug-resistant bacteria. The biofilm is the first line of defence for these drug-resistant microorganisms, a polymer-like structure of proteins and secretions that protects the colony from virtually everything but burning or scraping it away.

ABD does away with this problem in dramatic fashion. A natural biocidal agent derived from marine microorganisms, ABD is devastating for bacterial contamination, but gentle enough to be used as a supplement for antibiotic treatments. It is 99.99% effective at removing existing biofilms, prevents 99.99% of new biofilms from forming, and inhibits the growth of new bacterial colonies by over 92%. Lonza Group AG has verified this stellar performance in-vitro.

Aequor intends to use the funds from the SME instrument to study the EU and global market for biocides further, and to dig deeper into markets for antibiotic supplements. Further it will carry out growth projections and examine the process for clinical trials in-depth.

Fields of science (EuroSciVoc)

Programme(s)

Topic(s)

Funding Scheme

SME-1 - SME instrument phase 1

See all projects funded under this funding scheme

Call for proposal

(opens in new window) H2020-SMEInst-2016-2017

See all projects funded under this call

Coordinator

AEQUOR LTD
Net EU contribution
€ 50 000,00
Address
72 GREAT SUFFOLK STREET
SE1 0BL LONDON
United Kingdom
SME
Yes
Region
London Inner London — East Lewisham and Southwark
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Links
Total cost
€ 71 429,00